The dose threshold for nanoparticle tumour delivery
Source abstract
Abstract
Nanoparticle delivery to solid tumours over the past ten years has stagnated at a median of 0.7% of the injected dose. Varying nanoparticle designs and strategies have yielded only minor improvements. Here we discovered a dose threshold for improving nanoparticle tumour delivery: 1 trillion nanoparticles in mice. Doses above this threshold overwhelmed Kupffer cell uptake rates, nonlinearly decreased liver clearance, prolonged circulation and increased nanoparticle tumour delivery. This enabled up to 12% tumour delivery efficiency and delivery to 93% of cells in tumours, and also improved the therapeutic efficacy of Caelyx/Doxil. This threshold was robust across different nanoparticle types, tumour models and studies across ten years of the literature. Our results have implications for human translation and highlight a simple, but powerful, principle for designing nanoparticle cancer treatments.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (63)
Show source-provided references
1. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1, 16014 (2016).10.1038/natrevmats.2016.14 ↗
2. Rahman, Y. E., Cerny, E. A., Patel, K. R., Lau, E. H. & Wright, B. J. Differential uptake of liposomes varying in size and lipid composition by parenchymal and Kupffer cells of mouse liver. Life Sci. 31, 2061–2071 (1982).10.1016/0024-3205(82)90098-4 ↗
3. Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C. & Chan, W. C. W. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9, 1909–1915 (2009).10.1021/nl900031y ↗
4. Arnida, Janát-Amsbury, M. M., Ray, A., Peterson, C. M. & Ghandehari, H. Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur. J. Pharm. Biopharm. 77, 417–423 (2011).10.1016/j.ejpb.2010.11.010 ↗
5. Huang, X. et al. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano 5, 5390–5399 (2011).10.1021/nn200365a ↗
6. Juliano, R. L. & Stamp, D. The effect of particle size and charge on the clearance rates of liposomes and liposome encapsulated drugs. Biochem. Biophys. Res. Commun. 63, 651–658 (1975).10.1016/S0006-291X(75)80433-5 ↗
7. Albanese, A., Tang, P. S. & Chan, W. C. W. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14, 1–16 (2012).10.1146/annurev-bioeng-071811-150124 ↗
8. Tavares, A. J. et al. Effect of removing Kupffer cells on nanoparticle tumor delivery. Proc. Natl Acad. Sci. USA 114, E10871–E10880 (2017).
9. Wolfram, J. et al. A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery. Sci. Rep. 7, 1–13 (2017).10.1038/s41598-017-14221-2 ↗
10. Proffitt, R. T. et al. Liposoinal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science 220, 502–505 (1983).10.1126/science.6836294 ↗
11. Cheng, Y.-H., He, C., Riviere, J. E., Monteiro-Riviere, N. A. & Lin, Z. Meta-analysis of nanoparticle delivery to tumors using a physiologically based pharmacokinetic modeling and simulation approach. ACS Nano 14, 3075–3095 (2020).10.1021/acsnano.9b08142 ↗
12. Zhang, Y.-N., Poon, W., Tavares, A. J., McGilvray, I. D. & Chan, W. C. W. Nanoparticle–liver interactions: cellular uptake and hepatobiliary elimination. J. Control. Release 240, 332–348 (2016).10.1016/j.jconrel.2016.01.020 ↗
13. Liu, T., Choi, H., Zhou, R. & Chen, I. W. RES blockade: a strategy for boosting efficiency of nanoparticle drug. Nano Today 10, 11–21 (2015).10.1016/j.nantod.2014.12.003 ↗
14. Sun, X. et al. Improved tumor uptake by optimizing liposome based RES blockade strategy. Theranostics 7, 319–328 (2017).10.7150/thno.18078 ↗
15. Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W. & Kirpotin, D. B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 97, 4696–4740 (2008).10.1002/jps.21358 ↗
16. Tsoi, K. M. et al. Mechanism of hard-nanomaterial clearance by the liver. Nat. Mater. 15, 1212–1221 (2016).10.1038/nmat4718 ↗
17. Iio, M. & Wagner, H. N. Studies of the reticuloendothelial system (RES). I. Measurement of the phagocytic capacity of the RES in man and dog. J. Clin. Invest. 42, 417–426 (1963).10.1172/JCI104729 ↗
18. Allen, T. M. & Hansen, C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. BBA Biomembr. 1068, 133–141 (1991).10.1016/0005-2736(91)90201-I ↗
19. Laverman, P. et al. Preclinical and clinical evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose. J. Pharmacol. Exp. Ther. 293, 996–1001 (2000).
20. Utkhede, D. R. & Tilcock, C. P. Effect of Lipid dose on the redistribution and blood pool clearance kinetics of PEG-modified technetium-labeled lipid vesicles. J. Liposome Res. 8, 381–390 (2008).10.3109/08982109809035541 ↗
21. Kai, M. P. et al. Tumor presence induces global immune changes and enhances nanoparticle clearance. ACS Nano 10, 861–870 (2016).10.1021/acsnano.5b05999 ↗
22. Bouwens, L., Baekeland, M., de Zanger, R. & Wisse, E. Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology 6, 718–722 (1986).10.1002/hep.1840060430 ↗
23. Lee, S.-H., Starkey, P. M. & Gordon, S. Quantitative analysis of total macrophage content in adult mouse tissues: immunochemical studies with monoclonal antibody F4/80. J. Exp. Med. 161, 475–489 (1985).10.1084/jem.161.3.475 ↗
24. Park, J.-K. et al. Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine 12, 1365–1374 (2016).10.1016/j.nano.2016.01.013 ↗
25. Poon, W. et al. Elimination pathways of nanoparticles. ACS Nano 13, 5785–5798 (2019).10.1021/acsnano.9b01383 ↗
26. Ishida, T. & Kiwada, H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354, 56–62 (2008).10.1016/j.ijpharm.2007.11.005 ↗
27. Sasmono, R. T. et al. A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 101, 1155–1163 (2003).10.1182/blood-2002-02-0569 ↗
28. Kolb-Bachofen, V., Schlepper-Schäfer, J. & Kolb, H. Receptor-mediated particle uptake by liver macrophages. Exp. Cell Res. 148, 173–182 (1983).10.1016/0014-4827(83)90197-0 ↗
29. Commisso, C. et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497, 633–637 (2013).10.1038/nature12138 ↗
30. Canton, J. et al. Calcium-sensing receptors signal constitutive macropinocytosis and facilitate the uptake of NOD2 ligands in macrophages. Nat. Commun. 7, 11284 (2016).10.1038/ncomms11284 ↗
31. Lazarovits, J. et al. Supervised learning and mass spectrometry predicts the in vivo fate of nanomaterials. ACS Nano 13, 8023–8034 (2019).10.1021/acsnano.9b02774 ↗
32. Gordon, S. Phagocytosis: an immunobiologic process. Immunity 44, 463–475 (2016).10.1016/j.immuni.2016.02.026 ↗
33. Minchinton, A. I. & Tannock, I. F. Drug penetration in solid tumours. Nat. Rev. Cancer 6, 583–592 (2006).10.1038/nrc1893 ↗
34. Sykes, E. A., Chen, J., Zheng, G. & Chan, W. C. W. Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano 8, 5696–5706 (2014).10.1021/nn500299p ↗
35. Kingston, B. R., Syed, A. M., Ngai, J., Sindhwani, S. & Chan, W. C. W. Assessing micrometastases as a target for nanoparticles using 3D microscopy and machine learning. Proc. Natl Acad. Sci. USA 116, 14937–14946 (2019).10.1073/pnas.1907646116 ↗
36. Syed, A. M. et al. Three-dimensional imaging of transparent tissues via metal nanoparticle labeling. J. Am. Chem. Soc. 139, 9961–9971 (2017).10.1021/jacs.7b04022 ↗
37. Gabizon, A., Tzemach, D., Mak, L., Bronstein, M. & Horowitz, A. T. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Target. 10, 539–548 (2002).10.1080/1061186021000072447 ↗
38. Ohara, Y. et al. Effective delivery of chemotherapeutic nanoparticles by depleting host Kupffer cells. Int. J. Cancer 131, 2402–2410 (2012).10.1002/ijc.27502 ↗
39. Charrois, G. J. R. & Allen, T. M. Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity. J. Pharmacol. Exp. Ther. 306, 1058–1067 (2003).10.1124/jpet.103.053413 ↗
40. Simberg, D. et al. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA 104, 932–936 (2007).10.1073/pnas.0610298104 ↗
41. Souhami, R. L., Patel, H. M. & Ryman, B. E. The effect of reticuloendothelial blockade on the blood clearance and tissue distribution of liposomes. Biochim. Biophys. Acta 674, 354–371 (1981).10.1016/0304-4165(81)90366-4 ↗
42. Fernández-Urrusuno, R. et al. Effect of polymeric nanoparticle administration on the clearance activity of the mononuclear phagocyte system in mice. J. Biomed. Mater. Res. 31, 401–408 (1996).10.1002/(SICI)1097-4636(199607)31:3<401::AID-JBM15>3.0.CO;2-L ↗
43. Wagner, H. N. & Iio, M. Studies of the reticuloendothelial system (RES). III. Blockade of the RES in man. J. Clin. Invest. 43, 1525–1532 (1964).10.1172/JCI105029 ↗
44. Walkey, C. D., Olsen, J. B., Guo, H., Emili, A. & Chan, W. C. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134, 2139–2147 (2012).10.1021/ja2084338 ↗
45. Mcneil, S. E. Evaluation of nanomedicines: stick to the basics. Nat. Rev. Mater. 1, 16073 (2016).10.1038/natrevmats.2016.73 ↗
46. Wilhelm, S., Tavares, A. J. & Chan, W. C. W. Reply to “Evaluation of nanomedicines: stick to the basics”. Nat. Rev. Mater. 1, 16074 (2016).10.1038/natrevmats.2016.74 ↗
47. Autio, K. A. et al. Safety and eficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 4, 1344–1351 (2018).10.1001/jamaoncol.2018.2168 ↗
48. Fujiwara, Y. et al. A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Br. J. Cancer 120, 475–480 (2019).10.1038/s41416-019-0391-z ↗
49. Hrkach, J. et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci. Transl. Med. 4, 128ra39–128ra39 (2012).10.1126/scitranslmed.3003651 ↗
50. Rangarajan, S. et al. AAV5–factor VIII gene transfer in severe hemophilia A. N. Engl. J. Med. 377, 2519–2530 (2017).10.1056/NEJMoa1708483 ↗
51. Sindhwani, S. et al. The entry of nanoparticles into solid tumours. Nat. Mater. 19, 566–575 (2020).10.1038/s41563-019-0566-2 ↗
52. Szebeni, J., Simberg, D., González-Fernández, Á., Barenholz, Y. & Dobrovolskaia, M. A. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat. Nanotechnol. 13, 1100–1108 (2018).10.1038/s41565-018-0273-1 ↗
53. La-beck, N. M. & Gabizon, A. A. Nanoparticle interactions with the immune system: clinical implications for liposome-based cancer chemotherapy. Front. Immunol. 8, 6–11 (2017).
54. Jensen, A. I. et al. Remote-loading of liposomes with manganese-52 and in vivo evaluation of the stabilities of 52Mn-DOTA and 64Cu-DOTA using radiolabelled liposomes and PET imaging. J. Control. Release 269, 100–109 (2018).10.1016/j.jconrel.2017.11.006 ↗
55. Pulaski, B. A. & Ostrand-Rosenberg, S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. 39, 20.2.1–20.2.16 (2000).10.1002/0471142735.im2002s39 ↗
56. Albanese, A., Tsoi, K. M. & Chan, W. C. W. Simultaneous quantification of cells and nanomaterials by inductive-coupled plasma techniques. J. Lab. Autom. 18, 99–104 (2013).10.1177/2211068212457039 ↗
57. Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).10.1038/nmeth.2019 ↗
58. Adobe Photoshop 21.0.2 (Adobe, 2019).
59. Akima, H. A New Method of interpolation and smooth curve fitting based on local procedures. J. ACM 17, 589–602 (1970).10.1145/321607.321609 ↗
60. Sindhwani, S. et al. Three-dimensional optical mapping of nanoparticle distribution in intact tissues. ACS Nano 10, 5468–5478 (2016).10.1021/acsnano.6b01879 ↗
61. Berg, S. et al. ilastik: interactive machine learning for (bio)image analysis. Nat. Methods 16, 1226–1232 (2019).10.1038/s41592-019-0582-9 ↗
62. FlowJo Software v.10.0.7 (Becton, Dickinson and Company, 2019).10.1002/cprt.30365 ↗
63. GraphPad Prism v.8.4.0 (GraphPad Software).